Ejecutivos clave
| Nombre | Título | Pago | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO | 17.44M | -- | 1968 |
| Dr. Xiaobin Wu Ph.D. | President & COO | 12.22M | -- | 1962 |
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 31.75M | -- | 1963 |
| Mr. Chan Lee | General Counsel & Senior VP | 7.23M | -- | 1968 |
| Mr. Wang Lai Ph.D. | Global Head of R&D | 8.03M | -- | 1977 |
| Mr. Aaron Rosenberg | CFO & Principal Financial Officer | -- | -- | 1976 |
| Mr. Titus B. Ball | VP & Chief Accounting Officer | -- | -- | 1973 |
| Ms. Liza Heapes | Head of Investor Relations | -- | -- | -- |
| Mr. Yang Ji | Chief Compliance Officer | -- | -- | -- |
| Dr. Yan Qi | Senior VP & Head of Public Affairs - Greater China | -- | -- | -- |
BeiGene, Ltd.
- Sector:
- Healthcare
- Industria: Biotechnology
- Empleados a tiempo completo:
- 10,600
Descripción
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Gestión corporativa
Eventos próximos
February 24, 2025 at 10:59 AM UTC - February 28, 2025 at 12:00 PM UTC
BeiGene, Ltd. Fecha de utilidades
Eventos recientes
La información de Eventos recientes no está disponible